


FORM PTO-1449 (Rev. 2-32)	U. S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-090-Z	Serial No. 10/799,286
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Bakthavatchalam et al.	
		Filing Date: March 12, 2004	Group:

U. S. PATENT DOCUMENTS

No.	Examiner Initials	Date	Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
1.	7EB		4,424,205	3/18/82	LaHann et al.	424	72	01/03/84
2.			4,681,897	12/24/84	Brand	514	557	07/21/87
3.			4,812,446	07/17/87	Brand	514	165	03/14/89
4.			5,021,450	05/30/89	Blumberg	514	453	06/04/91
5.			5,290,816	06/21/90	Blumberg	514	691	03/01/94
6.			5,840,720	10/23/95	Chen	544	230.5	11/24/98
7.			5,962,532	03/12/98	Campbell et al.	514	627	10/05/99
8.			6,248,788	11/06/96	Robbins et al.	514	627	06/19/01
9.			6,437,147	03/16/01	Andersen et al.	548	304.1	08/20/02
10.	7EB		6,476,076	02/21/00	Lee et al.	514	580	11/05/02

U. S. PATENT APPLICATION PUBLICATIONS

No.	Examiner Initials	Date	Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
11.	7EB		2003/0133951	01/21/03	Coe et al.	424	239.1	07/17/03

EXAMINER <i>7EB</i>	DATE CONSIDERED <i>3/31/07</i>
----------------------------	---------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FOREIGN PATENT DOCUMENTS

No.	Examiner Initial	Date	Document Number	Name	Date	Country	Translation	
							Yes	No
12.	JEB	3/31/07	WO 99/00115	Benham et al.	07.01.1999	PCT		
13.			WO 01/85158	Hogestatt et al.	15.11.2001	PCT		
14.			WO 02/16317	Suh et al.	28.02.2002	PCT		
15.			WO 02/16318	Suh et al.	28.02.2002	PCT		
16.			WO 02/16319	Suh et al.	28.02.2002	PCT		
17.			WO 02/072536	Thompson et al.	19.09.2002	PCT		
18.			WO 02/076946	Culshaw et al.	03.10.2002	PCT		
19.	JEB	3/31/07	WO 02/090326	Rami et al.	14.11.2002	PCT		

OTHER DOCUMENTS

No.	Ex. Initials	Date	
20.	JEB	3/31/07	Bevan et al., "Capsazepine: a competitive antagonist of the sensory neuron excitant capsaicin," <i>Br. J. Pharmacol</i> 107:544-52 (1992)
21.			Caterina et al., "Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor," <i>Science</i> 288:306-13 (2000)
22.			Dickenson et al., "Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception," <i>Br. J. Pharmacol</i> 104:1045-1049 (1991)
23.			Kwak et al., "A capsaicin-receptor antagonist, capsazepine, reduces inflammation-induced hyperalgesic responses in the rat: evidence for an endogenous capsaicin-like substance," <i>Neuroscience</i> 86(2):619-626 (1998)
24.			Liu et al., "Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia," <i>Neuroscience Letters</i> 228:29-32 (1997)
25.			Ohkubo et al., "The Selective Capsaicin Antagonist Capsazepine Abolishes the Antinociceptive Action of Eugenol and Guaiacol," <i>J. Dent. Res.</i> 76(4):848-851 (1997)
26.			Santos et al., "Ruthenium red and capsazepine antinociceptive effect in formalin and capsaicin models of pain in mice," <i>Neuroscience Letters</i> 235:73-76 (1997)
27.			Szallasi, "Vanilloid Receptor Ligands," <i>Drugs and Aging</i> 18:561-573 (2001)
28.			Szallasi et al., "Vanilloid (Capsaicin) Receptors and Mechanisms," <i>Pharmacological Reviews</i> 51(2):159-211 (1999)
29.			Urban et al., "In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue," <i>Pain</i> 89:65-74 (2000)
30.		3/31/07	Wu et al., "Multiple Sensory and Functional Effects of Non-Phenolic Aminodimethylene Nonivamide: An Approach to Capsaicin Antagonist," <i>Gen. Pharmac.</i> 27:151-158 (1996)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		02-090-Z	10/798,286
		Applicant: Bakthavatchalam et al.	
		Filing Date:	Group:
		March 12, 2004	# 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FEB	1	4,439,606	3/27/1984	Du et al.			
	2	4,450,272	5/22/1984	Du et al.			
	3	4,659,710	4/21/1987	Susumu et al.			
	4	5,021,438	6/04/1991	Bodo et al.			
	5	5,354,747	10/1994	Hansen			
	6	5,430,033	7/1995	Cliffe et al.			
	7	5,442,064	8/15/1995	Pieper et al.			
	8	5,461,047	10/24/1995	Hansen Jr., et al.			
	9	5,756,504	5/26/1998	Bock et al.			
	10	5,789,412	8/4/1998	Halazy et al.			
	11	5,792,768	8/11/1998	Kalagowski et al.			
	12	5,840,720	11/24/1998	Ing-Jun			
	13	6,028,195	2/22/2000	Cho et al.			
	14	6,169,088	1/02/2001	Matsuno et al.			
	15	6,329,395	12/11/20001	Dugar et al.			

EXAMINER	DATE CONSIDERED
	3/21/07

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-090-Z	Serial No. 10/798,286
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: Bakthavatchalam et al.	
		Filing Date: March 12, 2004	Group: # 1614

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
72B	16	0 407 200 A1	09.01.1991	EP				
	17	0 882 717 A1	09.12.1998	EP				
	18	0 974 573 A1	26.01.2000	EP				
	19	1 122 242 A1	08.08.200	EP				
	20	WO 94/29286	22.12.1994	PCT				
	21	WO 96/01820	05.07.1995	PCT				
	22	WO 96/02525 A1	20.07.1995	PCT				
	23	WO 96/21648	10.01.1996	PCT				
	24	WO 98/00402	28.06.1997	PCT				
	25	WO 98/14431	01.10.1997	PCT				
	26	WO 98/20867	14.11.1997	PCT				
	27	WO 99/07672	24.07.1998	PCT				
	28	WO 99/51582	31.03.1999	PCT				
	29	WO 99/64394	07.06.1999	PCT				
↓	30	WO 00/27822	04.11.1999	PCT				
72B	31	WO 00/52001	03.03.2000	PCT				

EXAMINER	72 Zetton	DATE CONSIDERED	3/31/07
----------	-----------	-----------------	---------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		02-090-Z	10/798,286
		Applicant: Bakthavatchalam et al.	
		Filing Date:	Group:
		March 12, 2004	# 1614

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
738	32	WO 00/63171	20.04.2000	PCT				
70	33	WO 02/05819 A1	13.07.2001	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

728	34	Pan and Sun, Tetrahedron Letters (1998) 39:pp. 9505-9508.
728	35	Mokrosz, et al., J. Med. Chem. (1992) 35:2369-2374 note compound 31 on pate 2370..
728	36	Prasad et al., J. Med Chem. (1968) 11:1144-1150 note table 4.

EXAMINER		DATE CONSIDERED	
----------	---	-----------------	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.



205] Atty Dkt: 02-090-Z (NEU-02-090-Z)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bakthavatchalam et al.
Serial No. : 10/799,286
Filed : March 12, 2004
For : CAPSAICIN RECEPTOR LIGANDS
Examiner : K. Weddington
Group : 1614

SUPPLEMENTAL MODIFIED 1449 FORM

OTHER ART

Examiner
Initial

7KB

1. Advertisement for Labsystems' "Fluoroskan Ascent", Nature Biotechnology, back cover, January 1997.

7KB

2. "The FLIPR® System: Membrane Potential Assays," Retrieved October 6, 2005 from http://www.moleculardevices.com/pages/instruments/flipr_mp.html

7KB


3. Cortese, Jorge D., "At the Speed of Light: A look at the high-throughput fluorescence laboratory," The Scientist, 2000, 14:18. Retrieved October 6, 2005 from <http://www.the-scientist.com/>

7KB

4. Golebiowski et al., "Lead compounds discovered from libraries," Current Opinion in Chemical Biology, 2001, 5:273-284.

7KB

5. Hemmilä et al., "Time-resolved fluorometry: an overview of the labels and core technologies for drug screening applications," DDT, 1997, 2:373-381.



[270] Atty Dkt: 02-090-Z (NEU-02-090-Z)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Bakthavatchalam et al.
Serial No. : 10/799,286
Filed : March 12, 2004
For : CAPSAICIN RECEPTOR LIGANDS
Examiner : K. Weddington
Group : 1614

SUPPLEMENTAL MODIFIED 1449 FORM

U.S. PATENT DOCUMENTS

<u>Examiner Initial</u>	<u>Document Number</u>	<u>Issue Date</u>	<u>Name</u>
<u>KB</u>	23. 2004-0106616	6/2004	Bakthavatchalam et al.

FOREIGN PATENT DOCUMENTS

<u>Examiner Initial</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>
<u>KB</u>	24. 0 100 200	8/84	EP
<u>KB</u>	25. 0 790 240	8/1997	EP
<u>KB</u>	26. 1 122 242	8/2001	EP
<u>KB</u>	27. WO 00/17163	3/2000	PCT

OTHER ART

<u>Examiner Initial</u>	
<u>KB</u>	28. Acs G, Biro T, Acs P, Modarres S, Blumberg, P (1997) Differential activation and desensitization of sensory neurons by resiniferatoxin. J. Neurosci. 17:5622-5628.

75B

29. Blumberg PM, Szallasi A, Acs G (1993) Resiniferatoxin, an ultrapotent capsaicin analogue. In: Capsaicin in the study of pain (Wood JN, ed), pp 45-62. London: Academic.

75B

30. Dedov VN, Tran VH, Duke CC, Conner M, Christie MJ, Mandadi S, Roufogalis B (2002) Gingerols: a novel class of vanilloid receptor (VR1) agonists. Br. J. Pharmacol. 137:793-798.

75B

31. Someya A, Horie S, Yamamoto H, Murayama T (2003) Modifications of capsaicin-sensitive neurons in isolated guinea pig ileum by [6]-gingerol and lafutidine. J Pharmacol Sci 92:359-366

75B

32. Szallasi A, Blumberg PM (1990) Minireview: Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor. Life Sci 47:1399-1408.

75B

33. Szallasi A, Blumberg PM (1993) [³H]resiniferatoxin binding by the vanilloid receptor: species-related differences, effects of temperature and sulfhydryl reagents. Naunyn-Schmiedeberg's Arch Pharmacol 347:84-91.

75B

34. Szallasi A, Blumberg PM (1993) Mechanisms and therapeutic potential of vanilloids (capsaicin-like molecules). Advances in Pharmacology 24:123-155.

74B

6. Jerman et al., "Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology," Brit. J. Pharm., 2000, 130:916-922.

74B

7. Klopman et al., "Quantitative structure-agonist activity relationship of capsaicin analogues," Journal of Computer-Aided Molecular Design, 1995, 9:283-294.

74B

8. Kuntzweiler et al., "Rapid Assessment of Ligand Actions with Nicotinic Acetylcholine Receptors Using Calcium Dynamics and FLIPR," Drug Development Research, 1998, 44:14-20.

74B

9. Schroeder et al., "FLIPR: A New Instrument for Accurate, High Throughput Optical Screening," J. Biomolecular Screening, 1996, 1:75-80.

74B

10. Silverman et al., "New Assay technologies for high-throughput screening," Current Opinion in Chemical Biology, 1998, 2:397-403.

74B

11. Smart et al., "The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)," Brit. J. Pharm., 2000, 129:227-230.

74B

12. Szallasi et al., "Identification of Alpha-1-acid Glycoprotein (Orosomucoid) as a Major Vanilloid Binding Protein in Serum," J. Pharmacol. Exp. Therapeutics, 1992, 262:883-888.

74B

13. Szallasi et al., "Resiniferatoxin-type phorboid vanilloids display capsaicin-like selectivity at native vanilloid receptors on rat DRG neurons and at the cloned vanilloid receptor VR1," Brit. J. Pharm., 1999, 128:428-434.

74B

14. Szallasi et al., "The Cloned Rat Vanilloid Receptor VR1 Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons," Molecular Pharmacology, 1999, 56:581-587.

74B

15. Szallasi et al., "Vanilloid (Capsaicin) Receptor in the Rat: Positive Cooperativity of Resiniferatoxin Binding and Its Modulation by Reduction and Oxidation," J. Pharmacol. Exp. Therapeutics, 1993, 266:678-683.

74B

16. Tumosa et al., "Fluorescent EIA screening of monoclonal antibodies to cell surface antigens," J. Immun. Methods, 1989, 116:59-63.

75B

17. Wahl et al., "Iodo-Resiniferatoxin, a New Potent Vanilloid Receptor Antagonist," Molecular Pharmacology, 2001, 59:9-15.

76B

18. Walker et al., "The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain," J. Pharmacol. Exp. Therapeutics, 2003, 304:56-62.

77B

19. Walpole et al., "Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents: Structure--Activity Studies. 1. The Aromatic 'A-Region,'" J. Med. Chem., 1993, 36:2362-2372.

78B

20. Walpole et al., "Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents: Structure--Activity Studies. 2. The Amide Bond 'B-Region,'" J. Med. Chem., 1993, 36:2373-2380.

79B

21. Walpole et al., "Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents: Structure--Activity Studies. 3. The Hydrophobic Side-Chain 'C-Region,'" J. Med. Chem., 1993, 36:2381-2389.

80B

22. Wrigglesworth et al., "Analogues of Capsaicin with Agonist Activity as Novel Analgesic Agents: Structure--Activity Studies. 4. Potent, Orally Active Analgesics," J. Med. Chem., 1996, 39:4942-4951.